Clinical trials: Renal Allograft Recipients
Kidney Transplant
MMF vs. AZA for Kidney Transplantation
The Mycophenolate Steroid Sparing (MYSS) study demonstrated that, in the setting of a maintenance immunosuppressive regimen without steroids, mycophenolate mofetil (MMF) and azathioprine (AZA) provided the same efficacy in…
- Trial name
- ATHENA (NCT00494741)
- Testing
- mycophenolate mofetil, azathioprine
- Where
- 6 sites in Italy
- Volunteers
- 233 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Kidney Transplant; Complications
Esomeprazole or Pantoprazole in Renal Transplantation
prospective, parallel, open-label clinical trial was performed on forty-seven adult renal transplant recipients receiving immunosuppressive therapy with CsA doses adjusted to attain trough concentrations of 100-150 μg/L…
- Trial name
- NCT03812419
- Testing
- Esomeprazole 40 mg, Pantoprazole 40mg
- Volunteers
- 47 people
- Sponsor
- Future University in Egypt
Kidney Transplant Rejection
Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant Recipients
This study will evaluate the long term safety and efficacy of AT-1501 (tegoprubart) compared with tacrolimus in patients undergoing kidney transplantation.
- Trial name
- NCT06126380
- Testing
- AT-1501, Tacrolimus
- Where
- 43 sites in United States, Australia and 6 more
- Volunteers
- 132 people
- Sponsor
- Eledon Pharmaceuticals
Cytomegalovirus Disease
A Phase 3 Study of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus Disease
To compare the efficacy of oral brincidofovir (BCV) to valganciclovir (vGCV) for the prevention of cytomegalovirus (CMV) disease in kidney transplant allograft recipients who are CMV seronegative pretransplant and received a…
- Trial name
- SUSTAIN (NCT02439970)
- Testing
- Brincidofovir, Valganciclovir
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- Jazz Pharmaceuticals
Kidney Transplantation, Renal Transplantation
Tolerance by Engaging Antigen During Cellular Homeostasis
Anti-rejection medicines, also known as immunosuppressive drugs, are prescribed to organ transplant recipients to prevent rejection of the new organ.
- Conditions
- Kidney Transplantation, Renal Transplantation, Renal Transplant Recipient
- Trial name
- TEACH (NCT03504241)
- Testing
- Donor-derived Mesenchymal Stromal Cells, alemtuzumab, belatacept
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Transplant Dysfunction
Safety and Effect of Low-Energy Extracorporeal Shockwave Therapy (ESWT) on the Renal Allograft in Transplant Recipients.
The aim is to investigate the safety and potential effect of Low-energy Shockwave Therapy (ESWT) on the transplanted kidney. The treatment consist of ESWT two times a week for three weeks, six treatments in total.
- Trial name
- NCT03602807
- Testing
- Extracorporeal Shockwave Therapy
- Where
- Denmark
- Volunteers
- 40 people
- Sponsor
- Odense University Hospital
Kidney Transplantation
CAMPath and BELimumab for Transplant Tolerance in Sensitized Kidney Transplant Recipients
The purpose of this research study is to determine whether kidney transplant recipients who receive belimumab (Benlysta®), combined with the standard of care medications for kidney transplant recipients, is safe and effective in…
- Trial name
- CAMPBEL (NCT03591380)
- Testing
- Belimumab
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Wisconsin, Madison
Kidney Failure, Graft vs Host Disease
Study Comparing Cyclosporine Dose Reduction vs. Cyclosporine Elimination in Kidney Transplant Recipients Taking Sirolimus
Compare kidney function as measured by calculated creatinine clearance (using the method by Nankivell)1 at 12 months after transplantation in subjects receiving induction therapy with cyclosporine microemulsion (CsA) and Rapamune…
- Trial name
- NCT00195468
- Testing
- CYCLOSPORINE
- Where
- 13 sites in Brazil, Mexico
- Volunteers
- 280 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Renal Transplantation
Study Comparing Conversion to Sirolimus vs. Continued Use of Calcineurin Inhibitors in Kidney Transplant Recipients
The purpose of this study is to determine the effect of conversion from calcineurin inhibitor to sirolimus based therapy on renal function.
- Trial name
- NCT00038948
- Testing
- Sirolimus, tacrolimus, Cyclosporine A
- Volunteers
- 830 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
End Stage Renal Disease, Kidney Failure
C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI
The use of C1INH (Berinert) in patients receiving deceased donor kidney transplants with high risk for delayed graft function (DGF) may show significant improvement in outcomes post transplant compared with patients that do not…
- Conditions
- End Stage Renal Disease, Kidney Failure, Delayed Graft Function, Ischemic Reperfusion Injury
- Trial name
- C1INHDGF (NCT02134314)
- Testing
- C1 Esterase Inhibitor
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Cedars-Sinai Medical Center
Kidney Transplantation
A Safety and Efficacy Study of FCR001 Cell Therapy in Previously Transplanted Living Donor Kidney Recipients
An open-label study to assess the safety, tolerability, and efficacy of FCR001 cell therapy in adult recipients 3-12 months after kidney transplantation from a living donor.
- Trial name
- FREEDOM-2 (NCT01649388)
- Testing
- FCR001
- Where
- 3 sites in United States
- Sponsor
- Talaris Therapeutics Inc.
Renal Transplant Rejection
Randomized Conversion of Calcineurin-Inhibitors in Renal Allograft Recipients
This study is being done to investigate the impact of changing immunosuppressive medications from tacrolimus (Prograf®) to sirolimus (Rapamune®) between 6 and 24 months post transplant.
- Trial name
- NCT00866879
- Testing
- Sirolimus, Demographic Data, Medical History, and Donor Data, Blood Draws for Control Group
- Where
- United States
- Volunteers
- 275 people
- Sponsor
- Northwestern University
Kidney Failure
Prospective Study of Urinary Markers of Fibrosis in Kidney Transplants
The purpose of this study is to determine whether urinary connective tissue growth factor (uCTGF) can predict the onset of fibrosis in transplanted kidneys.
- Trial name
- NCT01982903
- Where
- Belgium
- Volunteers
- 180 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Kidney Transplant Recipients
Validation of Gene Expression Markers of Renal Allograft Functional Decline
The purpose of this study is to determine if certain genes found in a kidney biopsy performed at one-year post transplant can predict which transplanted kidneys will have decreased kidney function within five years…
- Trial name
- NCT01782586
- Where
- 4 sites in United States
- Volunteers
- 499 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Renal Transplantation
TAIZ -Monocytes for the Induction of Donor Specific Tolerance in Renal Allograft Recipients (Cadaver Kidney)
Induce tolerance or reduce the amount of immunosuppression after renal transplant patient (receiving cadaver kidney)with so called TAIZ-monocytes
- Trial name
- NCT00223093
- Testing
- TAIZ
- Volunteers
- 10 people
- Sponsor
- University Hospital Schleswig-Holstein
Primary Renal Allograft
Study to Evaluate Safety and Efficacy of Early Calcineurin Inhibitor Withdrawal in Primary Renal Allografts
Evaluate the safety and efficacy of early corticosteroid withdrawal and simultaneous calcineurin inhibitor withdrawal in recipients of primary renal allografts maintained long-term on MMF and sirolimus.
- Trial name
- NCT00374647
- Testing
- mycophenolate mofetil, sirolimus
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- University of Cincinnati
Skin Neoplasms, Kidney Transplantation
Study Evaluating the Effect of Sirolimus on Non-Melanoma Skin Cancer in Kidney Transplant Recipients
The purpose of this study is to determine the effect of sirolimus on the prevention of new non-melanoma skin cancer (NMSC) in kidney transplant recipients.
- Trial name
- NCT00129961
- Testing
- sirolimus, cyclosporine or tacrolimus
- Where
- 23 sites in United States, Australia and 2 more
- Volunteers
- 86 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Acute Allograft Rejection in Simultaneous Kidney/Pancreas Transplant Recipients
A Trial of Two Daclizumab Dosing Strategies vs. No Induction Treatment With Tacrolimus, Mycophenolate Mofetil , & Steroids for the Prevention of Acute Allograft Rejection in Simultaneous Kidney/Pancreas Transplant Recipients
The purpose of the study is to determine the safety and efficacy of two dosing regimens of daclizumab in simultaneous kidney/pancreas transplant recipients.
- Trial name
- NCT00363116
- Testing
- Daclizumab
- Where
- 24 sites in United States, Canada
- Volunteers
- 298 people
- Sponsor
- University of Cincinnati
Organ Transplantation
Belatacept Post Depletional Repopulation to Facilitate Tolerance
Acute rejection is a common problem after a kidney transplant. Rejection can occur when the kidney recipient's immune system tries to attack (or reject) the new kidney.
- Trial name
- NCT00565773
- Testing
- Belatacept, Sirolimus, Alemtuzumab
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Allan D Kirk, MD, PhD
Liver Transplant
A Multicentre, Randomised, Open-label, Controlled, 12-month Follow-up Study to Assess Impact on Renal Function of an Immunosuppression Regimen Based on Tacrolimus Minimisation in Association With Everolimus in de Novo Liver Transplant Recipients.
Assuming greater efficacy in the prevention of acute rejection in the EVR arm with minimisation of TAC levels, the hypothesis of the present trial was that the introduction of EVR in combination with the minimisation of TAC…
- Trial name
- REDUCE (NCT02040584)
- Testing
- Minimisation of TAC, TAC + MMF + corticosteroids
- Where
- 20 sites in Spain
- Volunteers
- 217 people
- Sponsor
- Novartis Pharmaceuticals